Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes

被引：11

作者：

Angelini, Silvia ^{[1
,2
]}

Botticelli, Andrea ^{[1
]}

Onesti, Concetta Elisa ^{[1
,2
]}

Giusti, Raffaele ^{[2
]}

Sini, Valentina ^{[1
,3
]}

Durante, Valeria ^{[1
,2
]}

Strigari, Lidia ^{[4
]}

Gentile, Giovanna ^{[5
]}

Cerbelli, Bruna ^{[6
]}

Pellegrini, Patrizia ^{[2
]}

Sgroi, Valentina ^{[1
,2
]}

Occhipinti, Mario ^{[1
,2
]}

Di Pietro, Francesca Romana ^{[1
,2
]}

Rossi, Alessandro ^{[7
]}

Simmaco, Maurizio ^{[8
]}

Mazzuca, Federica ^{[1
,2
]}

Marchetti, Paolo ^{[1
,2
,5
]}

机构：

[1] Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy

[2] St Andrea Hosp, Dept Med Oncol, Via Grottarossa 1035, I-00189 Rome, Italy

[3] Santo Spirito Hosp, Rome, Italy

[4] Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, Rome, Italy

[5] Immacolata IDI IRCSS, Dermopat Inst, Rome, Italy

[6] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Rome, Italy

[7] Sapienza Univ Rome, Fac Med & Psychol, Rome, Italy

[8] Sapienza Univ Rome, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, Rome, Italy

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 05期

关键词：

Breast cancer; taxanes; polymorphisms; ABCB1; P-gp; cytochrome P450; GENETIC POLYMORPHISMS; PERIPHERAL NEUROPATHY; RANDOMIZED-TRIAL; OVARIAN-CANCER; HUMAN LIVER; PACLITAXEL; ABCB1; DOCETAXEL; EXPRESSION; CHEMOTHERAPY;

D O I：

10.21873/anticanres.11610

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Taxanes are widely used to treat breast cancer patients. Taxanes are metabolized in human liver by the cytochrome CYP3A and are substrate of ATP-binding cassette multidrug transporters ABCB1. Single-nucleotide polymorphisms (SNPs) in genes involved in taxanes' metabolism could affect the inter-individual variability in reported toxicities. Materials and Methods: In this retrospective study, 152 women, affected by breast cancer and receiving a taxane-based chemotherapy, were enrolled. A peripheral blood sample was taken for genotyping the following polymorphisms: CYP3A4* 1B (A>G), CYP3A5 * 3 (G>A) and ABCB1 (C1236T; C3435T). Results: We observed an association between ABCB1 3435 T/T and lower grade of toxicities (p=0.05). No other association were found for CYP 3A4 * 1B, 3A5*3 and ABCB1 C1236T. Conclusion: ABCB1 3435 T/T seems to be associated to lower rate of toxicity in patients receiving taxanes. Further prospective and larger studies should be performed to clarify the role of this polymorphism.

引用

页码：2633 / 2639

页数：7

共 50 条

[31] Radiation pneumonitis in breast cancer patients treated with taxanes: Does sequential radiation therapy lower the risk?
Beal, K
Hudis, C
Norton, L
Wagman, R
McCormick, B
BREAST JOURNAL, 2005, 11 (05): : 317 - 320
[32] Response to taxanes in triple negative breast cancer
Nilufer Bulut
Sadettin Kilickap
Ebru Sari
Kadri Altundag
Cancer Chemotherapy and Pharmacology, 2008, 63 : 189 - 189
[33] Risks and Benefits of Taxanes in Breast and Ovarian Cancer
Laura Boehnke Michaud
Vicente Valero
Gabriel Hortobagyi
Drug Safety, 2000, 23 : 401 - 428
[34] Response to taxanes in triple negative breast cancer
Bulut, Nilufer
Kilickap, Sadettin
Sari, Ebru
Altundag, Kadri
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 189 - 189
[35] Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab
Longo, Raffaele
D'Andrea, Mario
Sarmiento, Roberta
Gasparini, Giampietro
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 : S41 - S50
[36] Controversies in the management of adjuvant breast cancer with taxanes: Review of the current literature
Araque Arroyo, Patricia
Ubago Perez, Ruth
Cancela Diez, Barbara
Fernandez Feijoo, Maria Amalia
Hernandez Magdalena, Jorge
Hernandez, Miguel Angel Calleja
CANCER TREATMENT REVIEWS, 2011, 37 (02) : 105 - 110
[37] Strategies to Decrease Taxanes Toxicities in the Adjuvant Treatment of Early Breast Cancer
Tang, Shou-Ching
CANCER INVESTIGATION, 2009, 27 (02) : 206 - 214
[38] Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients
Tesch, M. E.
Chia, S. K.
Simmons, C. E.
LeVasseur, N.
BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (01) : 167 - 176
[39] Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials
Gines, Jordi
Sabater, Eliazar
Martorell, Clara
Grau, Maria
Monroy, Marta
Casado, Miguel A.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (07): : 485 - 498
[40] Cross-sensitivity between taxanes in patients with breast cancer
Alfonso Sánchez-Muñoz
Begoña Jiménez
Ana García-Tapiador
Gema Romero-García
Laura Medina
Víctor Navarro
Luis Alonso González-Sánchez
Emilio Alba
Clinical and Translational Oncology, 2011, 13 : 904 - 906

← 1 2 3 4 5 →